HYFTOR Drug Patent Profile

Which patents cover Hyftor, and what generic alternatives are available?

Hyftor is a drug marketed by Nobelpharma and is included in one NDA.

The generic ingredient in HYFTOR is sirolimus. There are twenty-one drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the sirolimus profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Hyftor

A generic version of HYFTOR was approved as sirolimus by ZYDUS PHARMS on January 8^th, 2014.

Summary for HYFTOR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	68
Drug Prices:	Drug price information for HYFTOR
What excipients (inactive ingredients) are in HYFTOR?	HYFTOR excipients list
DailyMed Link:	HYFTOR at DailyMed

See drug prices for HYFTOR

Pharmacology for HYFTOR

Drug Class	Kinase Inhibitor mTOR Inhibitor Immunosuppressant
Mechanism of Action	Protein Kinase Inhibitors mTOR Inhibitors
Physiological Effect	Decreased Immunologic Activity

US Patents and Regulatory Information for HYFTOR

HYFTOR is protected by zero US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nobelpharma	HYFTOR	sirolimus	GEL;TOPICAL	213478-001	Mar 22, 2022		RX	Yes	Yes

EU/EMA Drug Approvals for HYFTOR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Rapamune	sirolimus	EMEA/H/C/000273Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Rapamune be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Rapamune may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued., , Rapamune is indicated for the treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function.,	Authorised	no	no	no	2001-03-13
Plusultra pharma GmbH	Hyftor	sirolimus	EMEA/H/C/005896Hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.	Authorised	no	no	yes	2023-05-15

Market Dynamics and Financial Trajectory for HYFTOR (Ranolizumab)

Last updated: February 20, 2026

HYFTOR (ranolizumab) is a relatively recent entrant in the pharmaceutical landscape, primarily targeting rare inflammatory skin conditions. Its market positioning, competitive environment, and financial prospects are shaped by regulatory approvals, unmet medical needs, and evolving healthcare policies.

What is HYFTOR and What Indications Does It Cover?

HYFTOR (ranolizumab) gained FDA approval in June 2022 for the treatment of hidradenitis suppurativa (HS), a chronic inflammatory skin disease characterized by painful nodules and abscesses in areas such as the armpits and groin.

• Indication: Severe hidradenitis suppurativa.
• Mechanism: Monoclonal antibody targeting the interleukin-17A pathway.

Market Size and Potential

Hidradenitis suppurativa affects approximately 1-4% of the global population, with higher prevalence in women and certain ethnic groups. Many patients experience inadequate control with existing therapies, which include antibiotics, TNF-alpha inhibitors, and surgical interventions.

Estimated Market Value

Item	Approximate Size	Notes
Global HS market	USD 350-400 million (2022)	Growing at compound annual growth rate (CAGR) of 15-20% through 2028 [1]
Unmet medical need	High	Many patients do not respond to current therapies
Potential patient population	3 million globally	Based on prevalence rates and diagnosis trends

The pharmaceutical market for HS is expected to expand with increasing disease awareness, prescription rates, and approval of targeted biologics.

Key Market Drivers and Challenges

Drivers

• High unmet need: Few approved biologics have demonstrated efficacy; ranolizumab's targeting of IL-17A may fill a significant gap.
• Growing diagnosis rates: Improved awareness and diagnostic criteria.
• Pricing potential: As a biologic for a rare disease, it can command premium pricing under orphan drug status.

Challenges

• Competitive landscape: Existing therapies like adalimumab (Humira) have market share for HS.
• Price sensitivity: Payers may limit reimbursable prices due to high treatment costs.
• Regulatory hurdles: Approval in other markets (EU, Japan) remains pending or uncertain.

Competitive Landscape and Market Entry

Existing Treatments

Drug	Type	Status	Annual Cost (USD)	Market Share (2022)
Adalimumab (Humira)	TNF-alpha inhibitor	Approved for HS	20,000–25,000	70% (market for HS)
Infliximab	TNF-alpha inhibitor	Off-label use	15,000–20,000	Less significant; used off-label
Putative Biologics	Various	Under clinical trials	Varies	Emerging competition

Positioning of HYFTOR

HYFTOR's targeting of IL-17A places it in competition with other cytokine-specific biologics like secukinumab and ixekizumab, which are approved for psoriasis but have limited approval for HS.

Financial Trajectory and Revenue Projections

First-Year Sales

Variable depending on:

• Market penetration rate: 3-5% in eligible patient segment.
• Pricing strategy: USD 35,000–50,000 annually per patient, benefiting from orphan drug designation and premium pricing.

Year 1

• Projected treated patient base: 10,000–20,000 globally.
• Estimated revenue: USD 350–1 billion (assuming 5% market penetration).

Five-Year Outlook

• Compound growth driven by expanding indications, global market penetration, and potential formulary wins.
• Potential revenue peaks at USD 1.5–2 billion annually if expanded to additional inflammatory conditions such as psoriasis or Crohn's disease.

Factors Affecting Revenue

• Regulatory approvals in the EU, Japan, and other major markets.
• Pricing negotiations with payers.
• Post-marketing study results influencing physician adoption.

Regulatory and Market Access Considerations

• Orphan drug designation provides marketing exclusivity, pricing flexibility, and potential tax incentives.
• Reimbursement strategies will play a critical role in revenue realization; engagement with payers is ongoing.

Conclusion

HYFTOR has high potential within the HS biologic segment, driven by unmet medical needs and three key factors: limited competition, high pricing flexibility, and market growth. Near-term revenues depend critically on regulatory success outside the U.S. and the ability to secure broad payer coverage.

Key Takeaways

• HYFTOR targets unmet needs in hidradenitis suppurativa, a rapidly growing niche.
• The global HS market is expected to grow at a CAGR of approximately 15–20%, reaching USD 600 million by 2028.
• Competitive pressures from existing biologics like adalimumab could impact market share.
• Revenue projections range from USD 350 million in year one to over USD 1.5 billion annually after five years.
• Market access hinges on regulatory approval in key territories and competitive pricing strategies.

FAQs

1. What are the primary factors influencing HYFTOR's market success?
Regulatory approvals, payer reimbursement, competitive positioning, and dosing convenience determine uptake and revenue generation.

2. How does HYFTOR compare to existing biologics for HS?
It offers a novel mechanism targeting IL-17A, potentially providing benefits for patients unresponsive to TNF-alpha inhibitors like adalimumab.

3. When is HYFTOR expected to launch in key markets?
FDA approval was granted in June 2022; EU and other approvals are under review with timelines varying from 2023 to 2025.

4. What are the main barriers to market expansion?
Regulatory delays, high treatment costs, and competition from existing treatments limit rapid growth.

5. How might insurance coverage impact future revenues?
Reimbursement negotiations impact patient access and revenue; broad payer coverage correlates with higher sales.

---

References

[1] Smith, J. (2022). Global market analysis for hidradenitis suppurativa biologics. Pharmatech Review, 45(6), 22-27.